Table 2. Prevalence of antibodies to SARS-CoV-2 spike (full S ectodomain, S1 and S2 domains) and nucleoprotein in HOS-P, MIS-P and CTL children, France, April–June 2020 (n =184).
| Antigen | HOS-P SARS-CoV-2-positive n = 54 |
MIS-P SARS-CoV-2-positive n = 15 |
CTL SARS-CoV-2-negative n = 115 |
p (CTL vs HOS-P) | p (CTL vs MIS-P) | p (HOS-P vs MIS-P) | |||
|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | ||||
| S1 | 24 | 44.4 | 14 | 93.3 | 0 | 0.0 | < 0.0001 | < 0.0001 | 0.0008 |
| S2 | 49 | 90.7 | 15 | 100 | 0 | 0.0 | < 0.0001 | < 0.0001 | NS |
| N | 29 | 53.7 | 14 | 93.3 | 0 | 0.0 | < 0.0001 | < 0.0001 | 0.0058 |
| S1 or S2 or N | 54 | 100 | 15 | 100 | 0 | 0.0 | < 0.0001 | < 0.0001 | NS |
| Full S | 28 | 51.9 | 13 | 86.7 | 1 | 0.9 | < 0.0001 | < 0.0001 | 0.0181 |
CTL: SARS-CoV-2-seronegative control group; HOS-P: SARS-CoV-2-seropositive hospitalised patients who did not develop an MIS; MIS-P: SARS-CoV-2-seropositive patients with multisystemic inflammatory syndrome; NS: non-significant; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.